Franz Bernhard Humer
Lead Independent DirectorDr. Franz Bernhard Humer was Chairman of Board of Directors of Kallyope, Inc. from June 2023. He serves as Non-Executive Director at LetterOne Holdings S.A. He serves as Director of Breakthrough Properties (USA). He serves as Non-Executive Director at Letterone Investment Holdings S. A. since March 2022 and served as its Member of L1 Health Advisory Board in 2022. He served as Executive Chairman of the Board at Neogene Therapeutics, Inc. since October 2020 until January 2023. Dr. Humer served as Senior Independent Non-Executive Director at Arix Bioscience plc since June 7, 2016 until December 17, 2019. He serves as Member of Advisory Board of L1 Health LLC. He has been a Venture Partner and Senior Advisor at Pappas Capital, LLC since December 2013 and December 10, 2013 respectively. He has been Independent Director of Allogene Therapeutics, Inc. since April 2018 and serves as its Lead Independent Director since 2025. He serves as the Chairman and Chief Executive at F. Hoffmann-La Roche Ltd. He serves as an Adviser of TamasekHoldings (Private) Limited and WISeKey SA. He served as the Chief Executive Officer of Roche Holding AG from April 2001 to March 2008 and also served as its Chairman since March 2008 until March 2014. He served as the Head of Pharmaceuticals Division and Chief Operating Officer at F. Hoffmann-La Roche Ltd. since 1996 until 1998. During this period, he transformed the Roche, including refining its focus on cancer therapies and completed the acquisition of Genentech. Dr. Humer joined Roche Group in 1995 as the Head of its Pharmaceuticals Division and served as its Chief Executive Officer from 1998 to 2001. He served as Chairman of the Board at Roche Holding AGHe served as Group Chief Executive Officer of Roche Diagnostics Corporation until March 2008. Dr. Humer served as the Director of Marketing Development & Product Licensing and Chief Operating Officer of Glaxo Pharmaceutical Limited, UK and also served as its Managing Director since 1987. He served at ICME Zurich from 1971 to 1973. He began his career in the pharmaceutical industry from 1973 to 1981. Before joining Schering Plough Corporation as assistant to the Vice President of Europe, Africa, Middle East operations and General Manager of Ecuador, UK and Portugal. He was the Managing Director of Glaxo Pharmaceuticals UK Limited in 1987. After leaving Schering Plough, he held various Managerial positions including Director at Glaxo Holdings plc, where he was responsible for research, business development, manufacturing, commercial strategy. He served as an Area Manager of Southern Europe at Glaxo Holdings PLC from 1981 to 1995. He served as the Chief Operating Director of Glaxo Holdings PLC since 1992, where he was responsible for all Operations in many regions. He has a wealth of leadership experience in the pharmaceutical and life science industry. In 1995, Dr. Humer joined Hoffman- La Roche as a Member of its Board and the Head of its pharmaceuticals division, progressing to become Chairman and CEO in 2001 and between 2008 and 2014 the Chairman of Roche Pharmholding BV. He served as the Chairman at Roche Venture Fund. He serves as the Chairman of the Supervisory Board at Roche Deutschland Holding GmbH. He serves as the Chairman of the Board of Directors of the International Centre for Missing and Exploited Children and the Humer Foundation. He serves as the Chairman of the Friends of Phelophepa Foundation. He served as the Chairman of INSEAD Board of Directors. He is also Chairman of PCI Services; Bial Pharmaceuticals and an Advisor to Temasek Holdings. He serves as a Non-Executive Director at Bial Pharmaceuticals. In addition, he holds private Board appointments across industries and serves as a Non-Executive Director of Cydar, Chairman of HMNC Holding, a healthcare advisor to a number of international institutions. He has been an Independent Director of Bial Pharmaceuticals and WISeKey. He had been an Independent Director of Chugai Pharmaceuticals from 2002 until 2014. He serves as a Member of the International Advisory Council at Chugai Pharmaceutical Co., Ltd. He has been a Member of International Advisory Board at Allianz SE since January 1, 2010. He has been a Member of Advisory Board at L1 Health since June 6, 2016. He serves as Non-Executive Director at Emil Frey SA. He serves as a Member of LetterOne Health Investment Advisory Board. He is a Board Member of Salzburg University and Project Hope-Charity. He joined the Board of Diageo in 2005. He served as an Independent Director of Citigroup Inc. from April 17, 2012 to April 16, 2019. He served as the Chairman of Diageo plc from July 1, 2008 to January 1, 2017 and also served as its Independent Non-Executive Director from April 2005 to January 1, 2017. He resigned from Diageo in 2016. Dr. Humer served as the Chairman of Roche Holdings, Inc. from May 15, 2001 to March 2014. He served as the Chairman of the Supervisory Board at Roche Diagnostics GmbH. He serves as Vice Chairman at International Holding Ltd and Economiesuisse. He served as Vice Chairman and Independent Director of WISeKey International Holding AG from 2016 to May 31, 2017. He served as an Outside Director at Chugai Pharmaceutical Co. Ltd. since March 27, 2014. He served as a Non-Executive Director of Kite Pharma, Inc. from September 15, 2015 to October 2017. He served as an Executive Director/Director of Roche Holdings, Inc. from May 15, 2001 to March 2014. He served as the President of the Board of Management at Roche Holding AG. He served as a Director of F. Hoffmann-La Roche Ltd. He served as an Executive Director of Roche Holding AG since 1995. He served as an Executive Director of Glaxo Holdings Plc since 1989. He served as a Director of Genentech, Inc. from 1995 to April 2004. He served as a Director of Jacobs Holding AG since 2009. He served as a Director of Cadbury Limited until January 17, 2002. Dr. Humer served as a Director of U.K. beverage maker Cadbury PLC until January 17, 2002. He served as a Director of Swiss insurer Zurich Financial Services AG. He served as a Member of International Advisory Council at Chugai Pharmaceutical Co. Ltd. until March 27, 2014. He served as a Member of Supervisory Board at Allianz SE from May 4, 2005 to December 31, 2009 and also served as its Member of International Advisory Board and Joint Advisory Council. He served as the Chairman of the European Federation of Pharmaceutical Industries and Associations until June 2007. He is a Member of International Business Leaders' Advisory Council for the Mayor of Shanghai, JPMorgan International Council and International Advisory Board of the National Center for Missing and Exploited. He received the Oliver R. Grace Award for distinguished service in advancing cancer research in 2000. He has been awarded the Singapore Public Service Star and the "Grosses goldenes Ehrenzeichen mit dem Stern für Verdienste" of Austria. He started as a Management Consultant in Zurich. He has extensive exp
Positions
- Company NameAllogene Therapeutics, Inc.Stock CodeALLOPositionLead Independent Director
